Mycoplasma genitalium, a stealth female reproductive tract
- 44 Downloads
Mycoplasma genitalium was first isolated from the urethral swabs of two symptomatic men with urethritis in 1980. It is a sexually transmitted bacterium associated with a number of urogenital conditions in women like cervicitis, endometritis, pelvic inflammatory disease, infertility, and susceptibility to human immunodeficiency virus (HIV). However, M. genitalium may also act like a stealth pathogen at female reproductive tract, giving no symptoms. Its prevalence varies between different groups, with the average being 0.5–10% in the general population and 20–40% in women with sexually transmitted infections. The recommended treatment of this infection is azithromycin as a single 1-g dose. However, in recent years, macrolide resistance has increased which is significantly lowering the cure rate, being less than 50% in some studies. New treatment regimens need to be investigated due to increasing drug resistance. The discussion and suggestion of an algorithm for management of this infection is the highlight of this paper.
KeywordsMycoplasma genitalium Sexually transmitted infection Resistance Prevalence Treatment
Newton Sergio de Carvalho: Manuscript writing, data collection.
Gabriele Palú: Manuscript writing.
Steven S. Witkin: Data management, manuscript editing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 3.Dehon PM, McGowin CL Mycoplasma genitalium infection is associated with microscopic signs of cervical inflammation in liquid cytology specimens. J Clin Microbiol 52(7):2398–2405 [s.l.], 23 abr. 2014. American Society for MicrobiologyGoogle Scholar
- 8.Taylor-Robinson D, Jensen JS (2011) Mycoplasma genitalium: from Chrysalis to multicolored butterfly. Clin Microbiol Rev, p. 498–514Google Scholar
- 22.Sethi S, Singh G, Samanta P, Sharma M (2012) Mycoplasma genitalium: an emerging sexually transmitted pathogen. Indian J Med Res 136(6):942–955Google Scholar
- 30.Cohen CR, Nosek M, Meier A et al (2007) Mycoplasma genitalium infection and persistence in a cohort of female sex workers in Nairobi, Kenya. Sex Transm Dis 34(5):274–279Google Scholar
- 51.Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R (2008) Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis 47:1546–1553. https://doi.org/10.1086/593188 CrossRefGoogle Scholar
- 52.Tabrizi SN, Tan LY, Walker S, Twin J, Poljak M, Bradshaw CS, Fairley CK, Bissessor M, Mokany E, Todd AV, Garland SM (2016) Multiplex assay for simultaneous detection of Mycoplasma genitalium and macrolide resistance using PlexZyme and PlexPrime technology. PLoS One 11:e0156740. https://doi.org/10.1371/journal.pone.0156740 CrossRefGoogle Scholar
- 56.Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, Vodstrcil LA, Jensen JS, Hocking JS, Garland SM, Bradshaw CS (2015) Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis 60:1228–1236CrossRefGoogle Scholar
- 65.FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together - FDA Drug Safety Communication issued July 26, 2016 - https://www.fda.gov/drugs/drugsafety/ucm500143.htm)
- 67.Couldwell DL, Lewis DA (2015) Mycoplasma genitalium infection: current treatment options, therapeutic failure, and resistance-associated mutations. Infect Drug Resist 8:147–161Google Scholar